The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Salix Pharmaceuticals Ltd

Nasdaq: SLXP
Last

(U.S.) $118.45

Today's change+3.96 +3.46%
Updated December 18 4:00 PM EST. Delayed by at least 15 minutes.
 

Salix Pharmaceuticals Ltd

Nasdaq: SLXP
Last

(U.S.) $118.45

Today's change+3.96 +3.46%
Updated December 18 4:00 PM EST. Delayed by at least 15 minutes.

Salix Pharmaceuticals Ltd Hits New 20-day High

Salix Pharmaceuticals Ltd closed up sharply Thursday, rallying (U.S.)$3.96 or 3.46% to (U.S.)$118.45 and setting a new 20-day high. Over the last five days, shares have gained 11.59% and 31.70% year to date. Shares have outperformed the S&P 500 by 25.45% during the last year.

Key company metrics

  • Open(U.S.) $116.00
  • Previous close(U.S.) $114.49
  • High(U.S.) $121.51
  • Low(U.S.) $112.73
  • Bid / Ask(U.S.) $117.74 / (U.S.) $119.00
  • YTD % change+31.70%
  • Volume2,494,089
  • Average volume (10-day)1,652,766
  • Average volume (1-month)1,957,376
  • Average volume (3-month)2,724,968
  • 52-week range(U.S.) $83.26 to (U.S.) $172.98
  • Beta0.83
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward25.19×
  • Forward PEG1.78×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.27
Updated December 18 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-5.58%

Salix Pharmaceuticals Ltd has a net profit margin of -5.58%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.93%Sector:HealthcareIndustry:Pharmaceuticals - Generic & Specialty
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue355382384258
Total other revenue--------
Total revenue355382384258
Gross profit268278269201
Total cost of revenue8610411657
Total operating expense434334422162
Selling / general / administrative16612519580
Research & development51395336
Depreciation / amortization55555511
Interest expense (income), net operating--------
Unusual expense (income)77104-23
Other operating expenses, total--------
Operating income-8048-3896
Interest income (expense), net non-operating-44-42-42-15
Gain (loss) on sale of assets--------
Other--------
Income before tax-1256-8081
Income after tax-893-4452
Income tax, total-363-3629
Net income-893-4452
Total adjustments to net income--------
Net income before extra. items-893-4452
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-893-4452
Inc. avail. to common incl. extra. items-893-4452
Diluted net income-893-4452
Dilution adjustment000--
Diluted weighted average shares64756368
Diluted EPS excluding extraordinary itemsvalue per share-1.390.04-0.690.77
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.610.12-0.650.55